Skinbiotherapeutics Share Discussion Threads

[dave4545] 26/2/2018 12:26

Shake time

[bobalot] 26/2/2018 12:25

The BREAKOUT IS UPWARDS

[parob] 26/2/2018 12:18

Is this about to break out of the downtrend?

[bobalot] 26/2/2018 12:00

Along with a presentation on the 28th and March 8th here is another key presentation; this time in Paris --- the worlds centre for women's beauty products showing off Pharma Applications so it will be good for corporate partnering.

SkinBioTherapeutics‏ @SkinBioT

Company CEO Cath O’Neill to showcase SkinBioTherapeutics plc at Pharmabiotics2018 in Paris on March 15th. @Pharmabiotics #SBTX


10:40 AM - 26 Feb 2018



SkinBioTherapeutics will be presenting at the event just after lunch.

14:30am - 15:00pm
Investigating and Understanding the Role of the Skin Microbiota in Skin Disorders
Holger Brüggemann

[bobalot] 26/2/2018 11:50

The market is starting to wake up to SkinBio's potential in the cosmetic's sector -- high value and volume products....Excellent rise today.

[dave4545] 26/2/2018 11:43

Cannot buy 5000 now mm's need sellers

[matt123d] 26/2/2018 11:30

Added a few here, looks interesting

[dave4545] 26/2/2018 11:28

Only 15000 available online at 9p, why the interest today ?

[elrico] 26/2/2018 10:52

SkinBioTherapeutics
‏ @SkinBioT
14m14 minutes ago

Company CEO Cath O’Neill to showcase SkinBioTherapeutics plc at Pharmabiotics2018 in Paris on March 15th. @Pharmabiotics #SBTX

[elrico] 23/2/2018 16:22

Directors Talk interview.

[incanus] 23/2/2018 16:16

Did you go to the presentation?

[incanus] 23/2/2018 16:15

I don't use any of the sm sites. Can you post another link, Elric. x

[elrico] 23/2/2018 15:45

CFO presentation from IB in Manchester.

[bobalot] 23/2/2018 10:52

Skinbiotherapeutics (LON:SBTX)‘s stock had its “corporateR21; rating restated by equities research analysts at Northland Securities in a report issued on Wednesday.

[slartybartfaster] 22/2/2018 14:53

risky, elrico, Fine examples of real research and insight and not regurgitated rnss.

[elrico] 22/2/2018 14:04

Proactive articleSkin-health specialist SkinBioTherapeutics PLC (LON:SBTX) remains on track with the development of its three flagship programmes.In its half-year results statement covering the second half of 2017, the life sciences company said it ended the year with £3.6mln in cash, up from £400,000 or so a year earlier.READ: SkinBioTherapeutics awarded first patent in AustraliaDr Cath O'Neill, the company's chief executive officer, said that since the company's flotation last year, the team had consistently delivered on the objectives outlined in its Aim admission document.During the reporting period, the priorities were expanded to include the manufacturing and scale-up capability and testing of the initial formulations.The manufacture of the chemical compound has been successfully replicated and scaled-up by a third party to 50 times the volume currently produced in the laboratory.The company can now produce sufficient volumes to support the formulation work and the forthcoming cosmetic human study, and the next stage will be to achieve industrial size scale-up, which it is currently working on.In the meantime, the company is still debating whether to produce the formulation as a gel, a cream or a lotion.The progress made across all these areas has ensured that the company remains on track to start its first human study for the cosmetic application in the third quarter of this year. The execution and results of this study will be a key point for the development of the cosmetic product, which is already generating early, initial interest from potential commercial partners, O'Neill revealed.Anti-infection and eczemaElsewhere, further progress has been made with the anti-infection and eczema programmes.A 'time-course' study has confirmed that the frequency of application required for protection is three times daily; this indicates that for protection against the Staphylococcus aureus infection, for both the eczema and anti-infection programmes, an application will be required every five hours.In addition, the company has finalised a dosing level at which the technology can be used safely, for all three programmes.With this programme progression, the management team has been able to build upon extensive industry relationships and early-stage commercial discussions continue regarding both the cosmetic application and the core SkinBiotix technology, O'Neill revealed.READ: SkinBioTherapeutics technology gets double green light - next stop human studiesAs a pre-revenue company, the profit & loss numbers are not especially relevant, but for the record the loss before tax widened to £386,523 from £254,990 in the second half of 2016, partly reflecting an increase in research & development costs to £125,283 from £89,952 the year before."We have made significant progress in the past six months around our SkinBiotix technology and we are on track with the advancement of all three indications in cosmetics, anti-infection and eczema," O'Neill said."There is a growing awareness of our SkinBiotix platform technology from the skin healthcare industry, based on the reputation of our team and our 'science-led' business approach. With continued work on our technology and the start of human studies in Q3, we are building further value for shareholders and a strong position from which to hold potential commercial discussions," she added.Northland Capital Partners was looking forward to SkinBio sealing some licensing opportunities."The skin microbiome is becoming an increasingly important field of scientific research. SkinBioTherapeutics has observed that the cosmetic industry is transitioning to products and applications with scientific validation. Having this at its core, the key focus to date has centred on preparation for the initial human studies, which should lead to further commercial negotiations in partnering and licensing opportunities," the broker said.The shares were down half a penny at 8p in mid-morning trading. 

[elrico] 22/2/2018 12:59

Risky picked up on some very important points;

The ability to protect against Staphylococcus aureus infection, (a common skin pathogen whose resistant form, MRSA, is the main cause of Hospital Acquired Infections), is a significant scientific development and big step to realising an opportunity in the very large Healthcare Acquired Infection market.

The interims also highlight the company has scaled up lysate production 50X. Lysate scale up which was the biggest development risk in the admission document and whilst this is not industrial scale as yet this is a significant reduction in development risk. SBTX partners have also produced three different formulation options for the cosmetic application; a gel, a cream and a lotion. Again the incorporation of an active in a formulation is another step in the development path.

I don't know if like SOH, she drafts the RNS's - it would appear so because of the sciency wording, which to be fair, is difficult to move away from when your area of expertise is, science based. I would imagine, there are serious restriction of what can be said in an RNS. Perhaps the better place to explain in layman terms is proactive or director talk.

[riskybusiness1] 22/2/2018 11:52

In the report:'Further work has progressed well with the anti-infection and eczema programmes.A 'time-course' study has confirmed that the frequency of application required for protection is three times daily. This indicates that for protection against Staphylococcus aureus infection, for both the eczema and anti-infection programmes, application will be required every five hours.In addition, the Company has finalised a dosing level at which the technology can be used safely, for all three programmes. The team has also confirmed the modifying property of SkinBiotix(R) on the protein composition of the skin; the technology increases the expression of proteins which are essential for the barrier characteristics of skin.'This is absolutely huge in terms of protection against MRSA. Hospitals are dying for such technology the costs are in the multi billions and increasing due to the overuse of antibiotics. There is HUGE demand for this. Unfortunately the management have not RNSd any of this and it gets lost in a very wordy sciency annual report that the average retail investor will find boring. What the market needs to know is how this translates into potential and what this means commercially. Great science going on but no clue on how to excite the market hence the volumes and idiots selling 100,000 for 7 odd p.Retail investors drive the price and unfortunately until they learn how to engage them the share price is going nowhere fast. Very disappointed here though the science is looking brilliant and value will eventually be recognised following successful trials.

[albanyvillas] 22/2/2018 10:29

ggoing to 3p

[f3rdinand] 22/2/2018 10:17

If this goes to 5p I will pile in!